CN108042527B - Application of peucedanum praeruptorum dunn in preparing medicine for protecting liver injury - Google Patents

Application of peucedanum praeruptorum dunn in preparing medicine for protecting liver injury Download PDF

Info

Publication number
CN108042527B
CN108042527B CN201711269421.4A CN201711269421A CN108042527B CN 108042527 B CN108042527 B CN 108042527B CN 201711269421 A CN201711269421 A CN 201711269421A CN 108042527 B CN108042527 B CN 108042527B
Authority
CN
China
Prior art keywords
liver
liver injury
peucedanum praeruptorum
group
praeruptorum dunn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201711269421.4A
Other languages
Chinese (zh)
Other versions
CN108042527A (en
Inventor
杨兴鑫
俞捷
梁丽
顾雯
董金材
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yunnan University of Traditional Chinese Medicine TCM
Original Assignee
Yunnan University of Traditional Chinese Medicine TCM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yunnan University of Traditional Chinese Medicine TCM filed Critical Yunnan University of Traditional Chinese Medicine TCM
Priority to CN201711269421.4A priority Critical patent/CN108042527B/en
Publication of CN108042527A publication Critical patent/CN108042527A/en
Application granted granted Critical
Publication of CN108042527B publication Critical patent/CN108042527B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Botany (AREA)
  • Medicinal Chemistry (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to 1 coumarin component peucedanum praeruptorum dunn which is separated and prepared from peucedanum praeruptorum dunn and application thereof in preparing medicament liver injury protection medicaments and health care products. Through in vivo and in vitro experimental research, the peucedanum praeruptorum dunn monomer compound is found to have pharmacological activity of resisting drug-induced liver injury for the first time. The chemical components have good drug-resistant liver injury effect, and are beneficial to research and development of novel drug-resistant liver injury protection drugs and health care products.

Description

Application of peucedanum praeruptorum dunn in preparing medicine for protecting liver injury
Technical Field
The invention relates to the field of medicines, in particular to application of an effective monomer compound in a Chinese medicine radix peucedani in preparing a medicine for protecting liver injury.
Background
The liver is the largest digestive gland in the human body, dominates the metabolism of the human body and is a huge 'chemical plant' in the human body. Liver damage is a common pathological condition of many liver diseases, and is mainly manifested by hepatocyte necrosis or apoptosis, hepatocyte degeneration, hepatocyte steatosis, cholestatic damage and inflammatory reaction. Long-term liver injury is an important factor causing liver fibrosis, even liver cirrhosis and liver cancer.
Among the investigated people in China, the number of the liver injury reaches 1.3 hundred million, and the number of the death people is nearly 50 million due to the liver injury disease. In recent years, with the rapid increase of the types of clinical medicines and the increase of the probability of self-administration or random increase of the dosage of the medicines of patients, the incidence rate of the hepatic injury caused by the medicines is correspondingly increased, and more than 900 medicines (such as carbon tetrachloride, bromobenzene, halothane, antituberculosis drugs, antibiotics, non-steroidal anti-inflammatory drugs and the like) are determined to cause the hepatic injury caused by the medicines according to statistics. Therefore, drug-induced liver injury is seriously threatened to human health and life, and the protection of liver health is an irreparable task in front of us.
Modern medicine does not have specific medicines for treating drug-induced liver injury, and mostly adopts rest, diet regulation, vitamin supplement and symptomatic treatment (antiviral medicines, immunoregulation medicines and liver protection and enzyme reduction medicines are selected), so severe patients need to be forced to stop taking the medicines so as to avoid the liver injury. The traditional Chinese medicine and the preparation thereof are quite common in China for treating liver diseases at present, modern pharmacological research shows that a plurality of traditional Chinese medicines (comprising compound medicines, single medicinal materials and monomer components) can effectively treat or improve the drug-induced liver injury diseases, and the traditional Chinese medicines are popular day by day due to the positive liver-protecting curative effect, small toxic and side effects and multi-component and multi-target effect.
Radix Peucedani is the dried root of Peucedanum praeruptorum Dunn of Umbelliferae, and has effects of lowering qi, eliminating phlegm, dispelling pathogenic wind and clearing heat. Can be used for treating lung heat, phlegm stagnation, affection of exogenous wind-heat, cough, asthma, excessive phlegm, yellow and viscous phlegm, fullness and stuffiness in chest and diaphragm, etc.; its main pharmacological actions include resisting myocardial ischemia, resisting oxidation, resisting tumor, resisting bacteria, resisting inflammation, reducing blood pressure, relieving cough and eliminating phlegm, etc.
The radix Peucedani mainly contains coumarins, and angular dihydropyrane coumarins as effective components, such as praeruptorin A, praeruptorin B, praeruptorin C, praeruptorin D, and praeruptorin E. Recent researches prove that the main pharmacological effects of the coumarin components of the peucedanum include bacteriostasis, antioxidation, anti-inflammation, anti-tumor, myocardial protection, phlegm elimination, cough relieving and the like (inner Mongolian medicine, 2017, 2 (3): 142-. In addition, it has been found that peucedanum praeruptorum dunn has pharmacological activity against hyperlipidemia, hyperglycemia, nonalcoholic fatty liver disease, type 2 diabetes and the like (patent application No. 201710046028.2).
In addition, the coumarin compounds also widely exist in other traditional Chinese medicines (such as notopterygium root, angelica dahurica, fructus cnidii, fructus psoraleae and the like), and researches show that the coumarin compounds have various biological activities, such as HIV resistance, cancer resistance, blood pressure reduction, arrhythmia resistance, osteoporosis resistance, bacteria resistance and the like (Chinese traditional medicine journal, 2005, 30 (6): 410-414; Chinese new medicine journal, 2013, 22 (20): 2392-. In addition, some coumarin compounds have liver protection activity, including osthole (Chinese medicine pharmacology and clinic, 2006, 22 (2): 21-22), corallin (Arch Pharm Res, 1993,16 (1): 13-17) and 8-methoxy psoralen (Chinese modern application pharmacy, 2012, 29 (8): 682-; it is also found that 5 furocoumarins in Changium smyrnioides root bark have the activity of inhibiting liver cancer cell proliferation (Chinese J.T. J.Med., 2012, 18 (6): 203-.
However, until now, no pharmacological action of peucedanum praeruptorum dunn on drug-induced liver injury is reported.
Disclosure of Invention
The invention aims to provide application of effective components of radix peucedani in preparing a drug for protecting liver injury.
The compound researched by the invention relates to 1 dihydropyranocoumarin component separated and prepared from the Chinese medicinal material peucedanum praeruptorum, has the following chemical structure, can be separated and prepared from natural medicines, and can also be prepared by chemical synthesis.
Figure BDA0001495257320000021
Chemical structure of peucedanum praeruptorum dunn
The invention is realized by investigating the compound pair carbon tetrachloride (CCl)4) The survival rate of primary hepatocytes of injured suckling mice, the influence of alanine Aminotransferase (ALT), aspartate Aminotransferase (AST), Malondialdehyde (MDA) and superoxide dismutase (SOD), and the peucedanum praeruptorum B is found to have the effect of resisting drug-induced liver injury for the first time.
The invention examines the compound pair CCl4ALT and AST contents in blood serum of an injured mouse, liver morphology, influences of liver index, MDA, SOD and Glutathione (GSH) in liver, and influences of MDA, ATP enzyme activity and membrane potential in liver cell mitochondria, and the peucedanum praeruptorum B is found to have the effect of resisting drug-induced liver injury for the first time.
Pharmacological experiments show that the pharmacological activity of 1 monomer component in the peucedanum praeruptorum dunn for resisting the drug-induced liver injury can be used for preparing drugs and functional foods with corresponding effects, and the research and the development of novel drug-induced liver injury protection drugs and health care products are facilitated.
The medicament can be any pharmaceutically acceptable dosage form, including tablets, capsules, oral liquid, syrup, granules, pills, powder, ointment, pellets, injection, suppositories, creams, sprays, dripping pills, patches, sustained-release preparations, controlled-release preparations and the like.
The oral liquid preparations may be in the form of aqueous or oily solutions, suspensions, emulsions, syrups or elixirs, which may contain conventional additives, including solvents such as water, ethanol and the like, suspending agents such as sorbitol, syrup, methyl cellulose, gelatin, hydroxyethyl cellulose and the like, emulsifying agents such as lecithin, sorbitan monooleate, acacia and the like, and preservatives such as p-hydroxybenzoic ester, propylparaben, sorbic acid and the like.
The oral solid preparation may contain conventional excipients such as binders, fillers, diluents, lubricants, disintegrants, coloring agents, flavoring agents and wetting agents, and fillers suitable for coating tablets if necessary include cellulose, mannitol, lactose and other similar fillers. Suitable disintegrants include starch, polyvinylpyrrolidone and starch derivatives, such as sodium starch glycolate. Suitable lubricants include magnesium stearate. Suitable wetting agents include sodium lauryl sulfate.
Drawings
FIG. 1 test monomer Compound Pair CCl4The effects of pathological changes of liver tissue of injured mice
Pathological change of mouse liver (x 200) of normal group (A), model group (B), silibinin group (C), peucedanum praeruptorin 8mg/kg group (D), peucedanum praeruptorin 16mg/kg group (E) and peucedanum praeruptorin 32mg/kg group (F)
The normal group liver tissue structure is clear and visible, the liver cells are arranged in order and have consistent size, the liver cell cables are obviously radial, and the sink area has no pathological changes such as degeneration, necrosis, inflammatory cell infiltration and the like; the liver cells of the mouse in the model group are obviously edematous, ballooning, disorderly arranged liver cords, and have punctate necrosis, and the liver parenchyma has more inflammatory cell infiltration; the visible inflammatory cell infiltration of the liver tissue of the silybin group is obviously reduced compared with that of the model group, and the liver cells have no obvious change; the dose groups of peucedanum praeruptorum B have inflammatory cell infiltration with different degrees, but are obviously reduced compared with the model group.
Detailed Description
In order to better explain the substance content of the invention which can be used for preparing the drug for protecting liver injury and the health care product, the invention is further explained by the specific experimental examples. The following examples are illustrative and are not intended to limit the invention in any way.
Example 1: effect of test monomeric Compounds on carbon tetrachloride-injured primary hepatocytes of suckling mice
1 materials, reagents and apparatus
1.1 Main materials and reagents
The test compound control (Peucedanum praeruptorum dunn, Silibinin) was purchased from Doppel Biotechnology GmbH; l-02 cells (Shanxi Yuan Biotech Co., Ltd.); DMEM/F12 medium (Gibco, USA); fetal bovine serum (Gibco, USA); CCK-8 cell proliferation assay kit (Solebao Biotechnology Co., Ltd.); carbon tetrachloride (CCl)4) (Sigma); penicillin streptomycin double antibody (Gibco, USA); PBS (sulibao biotechnology limited); 96-well cell culture plates (Thermo corporation); 0.22um filters (Corning); blood counting plates (dandri scientific medical supplies factory, zhenjiang); ALT, AST, SOD and MDA detection kit (Nanjing institute of bioengineering).
1.2 Main instruments
5％CO2Incubator (Thermo corporation); table centrifuges (Changshan instrument centrifuge instruments, Inc.); biosafety cabinets (suzhou decontamination equipment ltd); microplate reader (TECAN); -80 ℃ refrigerator (Thermo company).
2 method
2.1 preparation of test sample solution
An appropriate amount of each test compound control is dissolved in DMSO, and the test sample dissolved in DMSO is diluted to a desired concentration with physiological saline.
2.2 modeling and drug delivery
Cell plating: resuspend the cells to a concentration of 1X 10510000 cells (100. mu.L) per well per mL, 3 replicates of cells, 5% CO at 37 ℃2After 12h of culture, each experimental drug was treated for 24 h. Then, a final concentration of 10mmol/LCCl was added per well4Placing at 37 ℃ with 5% CO2And culturing for 6 h.
The experimental groups included: blank (medium only); a normal group; solvent control (1 ‰ DMSO); solvent control + CCl4(model group); silybin group (concentration 60. mu. mol/mL) + CCl4(positive control group); peucedanum praeruptorum dunn (concentration 80. mu. mol/mL, 160. mu. mol/mL, 320. mu. mol/mL) + CCl4。
2.3 cell viability assay (CCK-8 method)
Changing 100. mu.L/well serum-free medium, adding 10. mu.L/well CCK-8 stock solution, 5% CO2The mixture is incubated in an incubator for 2h, and the absorbance at 450nm is measured.
2.4 determination of ALT, AST, MDA, SOD content
The assay was performed according to the specific procedures of the kit instructions.
2.5 calculation and statistics
Cell viability (% relative number of viable cells) — a (dosed) -a (blank)/a (0 dosed) -a (blank) × 100;
SPSS17.0 software calculated and counted ANOVA one-way variance analysis significant differences (P < 0.05).
3 results of the experiment
Compound pair CCl4Influence of injured suckling mouse primary hepatocyte survival rate, ALT, AST, MDA and SOD
Silibinin (positive control) can play a role in protecting liver cells, and the research shows that the silybin can obviously improve CCl4The survival rate of the damaged liver cells, the ALT, AST and MDA contents and the SOD content are obviously reduced, which indicates that the cell pathological model is reliable. Like silybin, the CCl can be improved to a certain extent by using each dose group of peucedanum praeruptorum4Impaired hepatocyte survival whereinThe 160 mu g/mL and 320 mu g/mL groups have significant difference with the model group; moreover, the content of ALT, AST and MDA can be obviously reduced and the content of SOD can be obviously increased in each dose group of peucedanum praeruptorum dunn B, which shows that the compound has the activity of resisting drug-induced liver injury (table 1).
TABLE 1 test Compound vs CCl4The influence of primary hepatocytes survival, ALT, AST, MDA, SOD in the injured suckling mice (n ═ 3,
Figure BDA0001495257320000041
)
in comparison with the set of models,#P<0.05，##P<0.01，###P<0.001。
example 2: influence of tested monomeric compound on various indexes of mouse liver and serum damaged by carbon tetrachloride
1 materials, reagents and apparatus
1.1 animals
The male clean-grade Kunming mouse of 5-6 weeks old weighs 18-22 g, is purchased from Liaoning Changsheng biotechnology Limited company, and has a quality qualification certificate number: SCXK (Liao) 2015-0001. Before the experiment, all animals were adapted to 3 days. During the acclimatization period, animals had free access to food and free access to water. Keeping the breeding room quiet, keeping the indoor temperature at 23-25 ℃, keeping the humidity at 55% -75%, lighting by a fluorescent lamp, keeping the lighting for 12h and dark for 24h every day.
1.2 Main materials and reagents
The tested compound reference substances (Peucedanum praeruptorum dunn and Silibinin) are purchased from Dupfield biotechnology, Inc.; ALT, AST, MDA, SOD, GSH, Na+-K+-ATPase, Ca2+-Mg2+ATP enzyme assay kits are purchased from Nanjing institute of bioengineering; the BCA protein concentration determination kit is purchased from Biyuntian biotechnology research institute; CCl4And (5) analyzing and purifying.
1.3 Main instruments
MILLI-Q ULTRASONICPure water systems (Millipore, USA); electron analytical balance, PB-10pH meter (Sartorius, Germany); glass homogenizers (Ningbo Xinzhi Biotech, Inc.); UV-1800PC type UV-visible spectrophotometer (soaring technologies, Inc. Shanghai); infinite M200Pro multifunctional microplate reader (Dongsheng Innovation Biotechnology Co., Ltd.);
Figure BDA0001495257320000051
plus384 light-absorbing microplate reader (Molecular Devices, usa); HR/16M high speed refrigerated centrifuge (Hunan Hexi instrumentation, Inc.).
2 method of experiment
Male mice of Kunming species, randomly divided into 6 groups of 10 mice each, normal (normal saline) and model (0.1% CCl)4Peanut oil), silibinin (positive control group, 16mg/kg), and praeruptorin low-medium dosage group (8mg/kg, 16mg/kg, 32 mg/kg); each group of mice was gavaged with 10mL/kg for 7 days 1 time a day, and the molding was started 1h after the last administration. Mixing CCl4Dissolving in peanut oil to obtain 0.1% CCl4And (3) carrying out intraperitoneal injection on the peanut oil solution according to the dose of 10mL/kg, and establishing a mouse acute liver injury model. Normal groups were injected intraperitoneally with equal amounts of peanut oil.
After poisoning, fasting is performed without water prohibition, 16h later, the eyeball is picked to take blood, the whole blood is placed at room temperature for 2h, and then serum is separated and stored at-80 ℃ for later use; immediately taking blood, removing cervical vertebra to kill the mouse, quickly dissecting liver, rinsing with 4 deg.C pre-cooled physiological saline to remove surface floating blood, wiping with filter paper, weighing, and calculating liver index. Selecting 3 mice from each group, taking the liver at the same position, cutting tissue blocks, and fixing in 10% formalin for 24h for pathological section examination; storing the rest liver in a refrigerator at-80 deg.C, taking out when detecting, weighing 0.2g of the liver, placing in a glass homogenizer, shearing, adding 2mL of pre-cooled normal saline, making into 10% tissue homogenate in ice water bath, centrifuging at 3000rpm for 10min, and storing the supernatant at 4 deg.C for use.
3 index detection
3.1 liver index
The livers were dissected and weighed, and the liver index was calculated as [ weight of liver g/weight g ] x 100%.
3.2 serum Biochemical index determination
The ALT and AST in the serum are measured by an improved Reishi method according to the specific steps of the kit instruction.
3.3 Biochemical index determination of liver tissue
Taking 100 mu L of liver tissue homogenate, and measuring the contents of MDA, SOD and GSH in the liver tissue according to the operation of a kit instruction.
3.4 histopathological Observation
Liver tissue is fixed in 10% formalin fixing solution for 24 hr, washed with water, gradient-eluted with ethanol, xylene-transparent, paraffin-embedded, cut into 4 μm thick slices, and observed by HE staining.
3.5 hepatocyte mitochondria-related indices
3.5.1 hepatocyte mitochondrial isolation
Taking out mouse liver stored in refrigerator at-80 deg.C, cutting liver tissue of each group, washing residual blood with pre-cooled physiological saline, trimming connective tissue, sucking water with filter paper, and weighing (about 0.1 g); transferring the liver tissue to a pre-cooled glass homogenizer tube orifice, shearing the liver tissue into a non-obvious tissue block by using pre-cooled scissors, adding 1mL of pre-cooled mitochondrion separating medium (0.21M mannitol, 0.07M sucrose, 10mM Tris base, 1mM EDTA, 0.5mM EGTA, pH to 7.4), and homogenizing for 10 times in ice-water bath; transferring the tissue homogenate liquid into 1.5mL centrifuge tubes respectively, centrifuging at 4 ℃ and 1000 Xg for 10min, discarding the precipitate, transferring the supernatant liquid into another centrifuge tube, centrifuging at 4 ℃ and 10000 Xg for 10min, and obtaining the precipitate, namely the hepatocyte mitochondria.
3.5.2 hepatocyte mitochondrial Membrane potential assay
Extracting liver cell mitochondria, adding mitochondrial membrane potential measuring medium (0.25M sucrose, 5mM MgCl2, 10mM KCl, 5mM KH2P04, 10mM Hepes, 10mM succinate, pH 7.4), mixing to obtain suspension, and measuring mitochondrial protein concentration by using BCA protein concentration measuring kit; and adding 2.9mL of measuring medium into 100 mu L of mitochondrion suspension, adding 5 mu L of rhodamine 123, uniformly mixing, keeping the temperature at 37 ℃ for 30min, and measuring the fluorescence intensity at the excitation light wavelength of 484nm and the emission wavelength of 534 nm.
3.5.3 determination of liver cell mitochondria MDA content and ATPase activity
Extracting liver cell mitochondria, adding normal saline, mixing uniformly to form suspension, and measuring the protein concentration of the mitochondria by using a BCA protein concentration measuring kit; respectively taking 100 mu L of mitochondria suspension, and measuring MDA and Na in liver cell mitochondria according to the operation of kit instructions+-K+-ATPase and Ca2+-Mg2+-the activity of an ATPase.
4. Statistical treatment of each group of data with mean ± standard deviation
Figure BDA0001495257320000061
Representing data processed using SPSS 11.0 statistical software analysis, comparison between groups using one-way analysis of variance, P<0.05 was considered statistically different.
5 results of the experiment
5.1 test monomer Compound Pair CCl4Effect of liver index in injured mice
Compared with the normal group, the liver weight and liver index of the model group mice are obviously increased, which indicates that the liver is damaged; compared with the model group, the liver weight and liver index of the silibinin group (positive control) mice are obviously reduced, which indicates that the silibinin can effectively relieve CCl4The resulting liver damage; like silibinin, the liver index of each dose group of peucedanum praeruptorum dunn is significantly reduced (compared with that of the model group), indicating that peucedanum praeruptorum dunn has the activity of resisting drug-induced liver injury (table 1).
TABLE 1 test monomer Compound vs CCl4Effect of liver index in injured mice: (
Figure BDA0001495257320000071
n＝10)
Figure BDA0001495257320000072
In comparison with the set of models,#P<0.05，##P<0.01，###P<0.001。
5.2 monomers testedCompound pair CCl4Influence of injured mouse serum ALT and AST
Compared with the normal group, the ALT and AST in the serum of the mouse in the model group are obviously increased, and the model building is successful; compared with the model group, ALT and AST in the serum of the mice in the silibinin group are obviously reduced, which shows that silibinin can effectively relieve CCl4The resulting liver damage; compared with a model group, the serum contents of ALT and AST of mice in each dose group of the peucedanum praeruptorum B are reduced to a certain extent, wherein the difference between the 16mg/kg dose group and the model group has significance, and the peucedanum praeruptorum B has the activity of resisting drug-induced liver injury (Table 2).
TABLE 2 test monomer Compound vs CCl4Influence of serum ALT and AST in injured mice: (
Figure BDA0001495257320000073
n＝10)
In comparison with the set of models,#P<0.05。
5.3 test monomer Compound Pair CCl4Effect of damaging MDA, SOD and GSH in mouse liver
Compared with the normal group, the MDA content in the liver of the mouse in the model group is obviously increased, the contents of SOD and GSH are obviously reduced, and the model building is successful; compared with the model group, the content of MDA in the liver of the mouse with the silibinin group is obviously reduced, and the content of SOD and GSH is obviously increased, which shows that the silibinin can effectively relieve CCl4The resulting liver damage; compared with the model group, each dose group of peucedanum praeruptorum dunn can reduce the content of MDA and increase the content of SOD and GSH to a certain extent, wherein the difference between the 8mg/kg dose group and the model group is significant, which indicates that the peucedanum praeruptorum dunn has the activity of resisting drug-induced liver injury (Table 3).
TABLE 3 test monomer Compound vs CCl4Influence of damaged mouse liver MDA, SOD and GSH content: (
Figure BDA0001495257320000075
n＝10)
Figure BDA0001495257320000076
Figure BDA0001495257320000081
In comparison with the set of models,#P<0.05，##P<0.01。
5.4 test monomer Compound Pair CCl4Effect of injuring mouse liver mitochondria MDA, ATPase and membrane potential
Compared with the normal group, the MDA content in liver mitochondria of the model group mice is obviously increased, and Na+-K+-ATPase and Ca2 +-Mg2+The activity of ATP enzyme is obviously reduced, the fluorescence intensity of mitochondria of liver cells is obviously increased, and mitochondrial membrane potential collapse is caused, which indicates that the modeling is successful; compared with the model group, the content of MDA in the liver of the mouse with the silibinin group is obviously reduced, and Na is+-K+-ATPase and Ca2+-Mg2+The activity of ATP enzyme is obviously improved, the fluorescence intensity of mitochondria is obviously reduced, thereby alleviating the degree of membrane potential collapse, and showing that silibinin can effectively alleviate CCl4Resulting in liver damage. Compared with the model group, the peucedanum praeruptorum dunn 8mg/kg dose group can obviously reduce the MDA content and increase the Na content+-K+-ATPase and Ca2+-Mg2+-the activity of an atpase; and the 16mg/kg dose group can obviously reduce the fluorescence value of mitochondria and relieve the collapse degree of membrane potential, and the result shows that the peucedanum root-bark element can resist drug-induced liver injury by regulating the function of mitochondria (Table 4)
TABLE 4 test monomer Compound vs CCl4Effects of Damage to mouse liver mitochondria MDA, ATPase and Membrane potential (
Figure BDA0001495257320000082
n＝10)
Figure BDA0001495257320000083
In comparison with the set of models,#P<0.05，##P<0.01。

Claims (1)

1. the application of peucedanum praeruptorum dunn in preparing medicine for protecting liver injury has the following structural formula:
Figure FDA0002276848380000011
the dosage form of the medicine is tablets, granules or capsules.
CN201711269421.4A 2017-12-05 2017-12-05 Application of peucedanum praeruptorum dunn in preparing medicine for protecting liver injury Expired - Fee Related CN108042527B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201711269421.4A CN108042527B (en) 2017-12-05 2017-12-05 Application of peucedanum praeruptorum dunn in preparing medicine for protecting liver injury

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201711269421.4A CN108042527B (en) 2017-12-05 2017-12-05 Application of peucedanum praeruptorum dunn in preparing medicine for protecting liver injury

Publications (2)

Publication Number Publication Date
CN108042527A CN108042527A (en) 2018-05-18
CN108042527B true CN108042527B (en) 2020-02-07

Family

ID=62122010

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201711269421.4A Expired - Fee Related CN108042527B (en) 2017-12-05 2017-12-05 Application of peucedanum praeruptorum dunn in preparing medicine for protecting liver injury

Country Status (1)

Country Link
CN (1) CN108042527B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110731960A (en) * 2018-07-19 2020-01-31 国家海洋局第三海洋研究所 Application of peucedanum praeruptorum and its analogue in preparing medicine for resisting inflammatory disease

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101904839A (en) * 2010-08-06 2010-12-08 中国人民解放军第二军医大学 Application of imperatorin in preparing medicament for preventing and treating hepatitis or liver injury
CN106727507A (en) * 2017-01-22 2017-05-31 中国药科大学 The medical usage of Praeruptorin B

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101265872B1 (en) * 2012-11-30 2013-05-22 순천대학교 산학협력단 Pharmaceutical composition for preventing or treating osteoporosis, comprising praeruptorin a or pharmaceutical salt thereof as an active ingredient
KR20150087145A (en) * 2014-01-21 2015-07-29 주식회사 엘지생활건강 Composition for improving skin

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101904839A (en) * 2010-08-06 2010-12-08 中国人民解放军第二军医大学 Application of imperatorin in preparing medicament for preventing and treating hepatitis or liver injury
CN106727507A (en) * 2017-01-22 2017-05-31 中国药科大学 The medical usage of Praeruptorin B

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
香豆素及其衍生物的应用研究进展;王华等;《化工时刊》;20090831;第23卷(第8期);40-43 *

Also Published As

Publication number Publication date
CN108042527A (en) 2018-05-18

Similar Documents

Publication Publication Date Title
Ji et al. Induction of apoptosis in HepG2 cells by solanine and Bcl-2 protein
JP4781771B2 (en) Tomato extract for cancer treatment
Wang et al. Tanshinone IIA attenuates neuronal damage and the impairment of long-term potentiation induced by hydrogen peroxide
Tang et al. Protective effect of kaempferol on LPS plus ATP-induced inflammatory response in cardiac fibroblasts
Seyfi et al. In vitro and in vivo anti-angiogenesis effect of shallot (Allium ascalonicum): a heat-stable and flavonoid-rich fraction of shallot extract potently inhibits angiogenesis
He et al. Antiangiogenic effects and mechanisms of trans-ethyl p-methoxycinnamate from Kaempferia galanga L.
Yuan et al. Efficacy of osthole for Echinococcus granulosus in vitro and Echinococcus multilocularis in vivo
WO2016169573A1 (en) Sesquiterpene lactones as potent and broad spectrum antiviral compounds against all genotypes of hepatitis c virus (hcv)
Tobeiha et al. Potential of natural products in osteosarcoma treatment: Focus on molecular mechanisms
Xu et al. Effects of aqueous extracts of Ecliptae herba, Polygoni multiflori radix praeparata and Rehmanniae radix praeparata on melanogenesis and the migration of human melanocytes
CN107753480B (en) Application of praeruptorin in preparation of drug for protecting liver injury
Mousavi et al. Novel Drug Design for Treatment of COVID‐19: A Systematic Review of Preclinical Studies
KR101887631B1 (en) Composition for delaying senescence, lifespan extension, or preventing, treating or improving of diseases caused by lipofuscin accumulation comprising sauchinone as an active ingredient of Saururus chinensis
Kang et al. Roots of Lithospermum erythrorhizon promotes retinal cell survival in optic nerve crush-induced retinal degeneration
Wang et al. Licorice flavonoids nanoparticles prepared by liquid antisolvent re-crystallization exhibit higher oral bioavailability and antioxidant activity in rat
CN108042527B (en) Application of peucedanum praeruptorum dunn in preparing medicine for protecting liver injury
Rollando et al. In vitro Cytotoxic Potential of Sterculia quadrifida Leaf Extract Against Human Breast Cancer Cell Lines.
Lai et al. Induction of angiogenesis in zebrafish embryos and proliferation of endothelial cells by an active fraction isolated from the root of astragalus membranaceus using bioassay-guided fractionation
Mou et al. Anti‐hepatitis B virus activity and hepatoprotective effect of des (rhamnosyl) verbascoside from Lindernia ruellioides in vitro
CN107875147B (en) Application of peucedanum praeruptorum dunn E in preparing drug for protecting liver injury
CN101926844A (en) Stellera chamaejasme L extract and anti-tumor action thereof
Kuchta et al. Tradition to pathogenesis: A novel hypothesis for elucidating the pathogenesis of diseases based on the traditional use of medicinal plants
Oliveira et al. Cytotoxicity, anti-poliovirus activity and in silico biological evaluation of constituents from Maytenus gonoclada (Celastraceae)
CN108030781A (en) Purposes of the Isomperatorin in drug induced hepatic injury protection medicine is prepared
US10272124B2 (en) Use of helminthostachys, ugonins or flavone-based compounds for the treatment or prevention of metabolic diseases

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20200207

Termination date: 20211205

CF01 Termination of patent right due to non-payment of annual fee